Urinary Toxicity After Radiotherapy For Prostate Cancer: Dose Maps To Identify Dose-effect Relationships
Main Category: Radiology / Nuclear MedicineAlso Included In: Prostate / Prostate Cancer; Urology / Nephrology; Cancer / Oncology
Article Date: 22 Sep 2008 - 4:00 PDT
|
|
| Patient / Public: | ![]() |
3 (1 votes) |
| Healthcare Prof: | ![]() |
After external radiotherapy for prostate cancer, patients can suffer from long-term urinary problems, including incontinence and obstruction. Many studies have investigated the relationship between urinary problems and the radiation dose the bladder was exposed to, as estimated during the planning of the treatment. Clear dose-effect relationships are, however, seldom reported. This could be due to the variable filling and position of the bladder during treatment, making the predicted position of the bladder more difficult and inconsistent. Furthermore, usually only the dose to the total bladder is analysed and local structures are not evaluated separately.
We studied whether dose maps of the bladder area adjacent to the prostate, could identify local dose-effect relationships for urinary problems. In a dose map, the dose in a defined anatomical region is mapped for each patient. By calculating the mean dose map of patients without a complaint, and subtracting this map from the mean dose map of patients with a complaint, we obtained dose difference maps. These maps visualised the local areas where patients with a complaint, received more dose than patients without that complaint.
From these dose difference maps we learned that patients suffering from obstruction received on average a much higher dose to the region where the ureters enter the bladder. Patients who reported cramps and/or pain requiring medication), received on average more dose to the bladder area close to the pubic bone.
This study provides very useful information on the development of urinary problems after radiothe¬rapy, not previously reported. In the near future, we will extend our analyses by evaluating other side effects of radiotherapy.
Heemsbergen Wilma et al. Netherlands Cancer Institute / Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands
About ESTRO 27
ESTRO 27 (September 14th to 18th, 2008) offered an outstanding scientific programme combining lectures from eminent invited speakers, proffered papers and poster discussions, teaching lectures on a wide range of topics including clinical issues, brachytherapy, radiobiology, physics and technology as well as debates on controversial topics and clinical case discussions, a special poster reception, poster discussion sessions and electronic poster viewing.
ESTRO 27 hosted the largest European exhibition in Radiotherapy with participation from all the leading manufacturers.
ESTRO 27
ESTRO (European Society for Therapeutic Radiology and Oncology)
Visit our radiology / nuclear medicine section for the latest news on this subject.
MLA
16 Feb. 2012. <http://www.medicalnewstoday.com/releases/122369.php>
APA
http://www.medicalnewstoday.com/releases/122369.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




